Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.

This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.

This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.

This case series evaluated the use of oral bicalutamide with low-dose oral minoxidil in women with female pattern hair loss who didn't respond to minoxidil alone, finding that 96.6% showed improvement after six months without adverse effects.

This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

This review highlights recent advancements in using nanotechnology to improve the function and delivery of PROTAC drugs, despite existing challenges like low solubility and poor permeability, aiming to enhance their potential in disease treatment.

This review discusses the dual role of cellular senescence in ageing and tissue repair and suggests potential therapeutic applications, with no new experimental results reported.

This workshop review discusses the dual role of cellular senescence in cancer, highlighting both its anticancer effects and pro-tumorigenic potential, while reporting no new research results.

This review discusses the role of the androgen receptor in breast cancer diagnosis and treatment, and notes a lack of new research results on its therapeutic potential.

This article reviews the potential for low intensity ultrasound as an antidote for the peripheral cytotoxic side effects of taxane drugs in chemotherapy, presenting no new clinical results.

In this study, researchers analyzed spaceflight data from various sources and found that skin issues during spaceflight are linked to DNA damage, mitochondrial dysregulation, and gene alterations, while also highlighting the skin's adaptability post-flight.

This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.

This review provides a comprehensive overview of multidisciplinary dermo-aesthetic interventions for breast cancer patients, aiming to establish safe protocols involving various specialists to improve quality of life, although consultation with an oncologist before treatment is advised.

This study found that topical cetirizine treatment significantly improved hair regrowth and patient satisfaction in male patients with androgenetic alopecia compared to a placebo, highlighting its potential role in treatment.

This review discusses the potential of 3D cell cultures, particularly Patient-Derived Organoids, in advancing research on liposarcoma by addressing limitations of 2D cultures and animal models but reports no new experimental findings.

In this study, XMU-MP-1 unexpectedly reduced cell proliferation and altered cell cycle progression in a model human hair follicle, possibly due to off-target kinase inhibition.

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.

This pharmacovigilance study identified 64 drugs linked to hair loss, revealing specific demographic trends and timing patterns, and emphasized the importance of gender-specific monitoring and label updates to better convey real-world risks.

This opinion piece discusses strategies for managing cancer-related alopecia, emphasizing personalized approaches including scalp cooling and topical minoxidil, but it reports no new clinical results.

Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.

This study introduces Kalya Research, an AI-driven tool designed to identify and categorize literature on complementary and alternative medicines, showing its effectiveness compared to Medline in finding relevant alopecia research within the context of breast cancer patients.

This study reviews drug-induced hair changes, noting that hair loss often reverses after stopping the drug, but permanent alopecia cases post-chemotherapy are rising.

The authors reported that both finasteride and oral contraceptives with drospirenone had a significant therapeutic effect on women with polycystic ovary syndrome, leading to pregnancies in both treatment groups.